Intracellular Delivery of Biomolecules to Induce Tolerance
Summary
EPO published patent application EP3452062A1 by SQZ Biotechnologies covering cell squeezing technology for intracellular delivery of biomolecules to induce immune tolerance. The patent application includes therapeutic claims across multiple immunological conditions and cell therapy compositions. The publication covers 31 designated contracting states.
What changed
EPO published patent application EP3452062A1 titled 'Intracellular Delivery of Biomolecules to Induce Tolerance' filed by SQZ Biotechnologies Company. The patent covers cell squeezing technology enabling intracellular delivery of biomolecules to modulate immune responses, with applications in treating immunological conditions and autoimmune diseases. The A1 publication indicates the application passed formal examination and includes search report.
Pharmaceutical companies and biotech firms developing cell-based therapies or drug delivery systems should evaluate potential overlap with this intellectual property. Medical device manufacturers in the cell therapy space may face freedom-to-operate considerations. Competitors pursuing similar intracellular delivery mechanisms should conduct IP landscape analysis to assess design-around requirements.
What to do next
- Review patent claims for freedom-to-operate implications
- Monitor for potential licensing opportunities in cell therapy delivery
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
INTRACELLULAR DELIVERY OF BIOMOLECULES TO INDUCE TOLERANCE
Publication EP3452062A1 Kind: A1 Apr 01, 2026
Applicants
SQZ Biotechnologies Company
Inventors
LOUGHHEAD, Scott, GILBERT, Jonathan, B., BERNSTEIN, Howard, SHAREI, Armon, R., MOORE, Finola
IPC Classifications
A61P 29/00 20060101AFI20251124BHEP A61P 37/02 20060101ALI20251124BHEP A61P 37/06 20060101ALI20251124BHEP A61P 37/08 20060101ALI20251124BHEP A61P 43/00 20060101ALI20251124BHEP C12N 5/0781 20100101ALI20251124BHEP C12N 5/0783 20100101ALI20251124BHEP A61K 40/11 20250101ALI20251124BHEP A61K 40/13 20250101ALI20251124BHEP A61K 40/22 20250101ALI20251124BHEP A61K 40/24 20250101ALI20251124BHEP A61K 40/41 20250101ALI20251124BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.